company background image
DUL logo

Alnylam Pharmaceuticals DB:DUL Stock Report

Last Price

€139.20

Market Cap

€17.7b

7D

3.3%

1Y

-20.6%

Updated

26 Mar, 2024

Data

Company Financials +

Alnylam Pharmaceuticals, Inc.

DB:DUL Stock Report

Market Cap: €17.7b

DUL Stock Overview

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference.

DUL fundamental analysis
Snowflake Score
Valuation3/6
Future Growth6/6
Past Performance0/6
Financial Health2/6
Dividends0/6

Alnylam Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Alnylam Pharmaceuticals
Historical stock prices
Current Share PriceUS$139.20
52 Week HighUS$195.40
52 Week LowUS$133.40
Beta0.39
1 Month Change-6.83%
3 Month Change-19.07%
1 Year Change-20.58%
3 Year Change23.01%
5 Year Change71.81%
Change since IPO2,740.82%

Recent News & Updates

Recent updates

Shareholder Returns

DULDE BiotechsDE Market
7D3.3%3.3%1.6%
1Y-20.6%35.8%6.4%

Return vs Industry: DUL underperformed the German Biotechs industry which returned 35.8% over the past year.

Return vs Market: DUL underperformed the German Market which returned 6.4% over the past year.

Price Volatility

Is DUL's price volatile compared to industry and market?
DUL volatility
DUL Average Weekly Movement5.7%
Biotechs Industry Average Movement5.9%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.2%
10% least volatile stocks in DE Market2.4%

Stable Share Price: DUL's share price has been volatile over the past 3 months.

Volatility Over Time: DUL's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20022,100Yvonne Greenstreethttps://www.alnylam.com

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer’s disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH.

Alnylam Pharmaceuticals, Inc. Fundamentals Summary

How do Alnylam Pharmaceuticals's earnings and revenue compare to its market cap?
DUL fundamental statistics
Market cap€17.68b
Earnings (TTM)-€406.48m
Revenue (TTM)€1.69b

10.5x

P/S Ratio

-43.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
DUL income statement (TTM)
RevenueUS$1.83b
Cost of RevenueUS$310.41m
Gross ProfitUS$1.52b
Other ExpensesUS$1.96b
Earnings-US$440.24m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-3.50
Gross Margin83.02%
Net Profit Margin-24.08%
Debt/Equity Ratio-1,086.8%

How did DUL perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.